Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab

descriptionPublicationkeyboard_double_arrow_right Article 28 Oct 2020Publisher:Publishing House OKIJournal:Kachestvennaya klinicheskaya praktika (issn: 2588-0519, eissn: 2618-8473,

Copyright policy )

Authors: K. B. Mirzaev; Yu. Yu. Kiselev; D. A. Sychev;

doi: 10.37489/2588-0519-2020-s4-23-27

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab

- Summary
- Subjects
- Metrics

Abstract

No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, when interleukin-6 blockers (tocilizumab, sarilumab) are unavailable.

Related Organizations

Oslo Metropolitan University
Norway

Keywords

RS1-441, Pharmacy and materia medica, covid-19, Medical technology, коронавирус, R855-855.5, метилпреднизолон

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average